Logo

Metabolon Inks IP, Development Agreement with U. Michigan for Prostate Cancer Dx

Oct 21, 2008
NEW YORK (GenomeWeb News) – Metabolon said today that it has signed an intellectual property and development agreement with the University of Michigan related to its Prostarix line of prostate cancer diagnostics.
 
Under the terms of the agreement, Metabolon has taken an exclusive license for prostate cancer aggressiveness biomarkers that were discovered in a previous collaboration between the company and the university.
 
The company said that the IP it has licensed will provide it with a “significant advantage” in the field of prostate cancer diagnosis and will serve as the basis for its Prostarix test, which it expects to launch in late 2009.
 
The agreement also includes a sponsored research agreement with UM assistant professor of pathology Arun Sreekumar that will focus on studying the role of the biomarkers in cancer aggressiveness.
 
Financial terms of the agreement were not released.

Breaking News
The Scan

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.

Algorithm Teases Out Genetic Ancestry in Individuals at Biobank Scale

Researchers develop an algorithm known as Rye to tease apart ancestry fractions in admixed individuals at a biobank-scale, applying it to 488,221 UK Biobank participants in Nucleic Acids Research.

Multi-Ancestry Analysis Highlights Comparable Common Variants at Complex Trait-Linked Loci

Researchers in Nature Genetics examine common variants implicated in more than three dozen conditions, estimating genetic effect similarities across ancestry tracts in admixed individuals.

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.